indication

Cognitive Dysfunction

Competitive landscape

as of 2026-07-01
Competitive set
2
2 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
37 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 42 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugNot Yet Recruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 31 trial
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039

Market size

prevalence as a range, not a number